MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
February 27, 2007
Brian Lawler
PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 29, 2007
Brian Lawler
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. mark for My Articles similar articles
The Motley Fool
April 27, 2007
Brian Lawler
PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 14, 2008
Brian Lawler
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business. mark for My Articles similar articles
The Motley Fool
July 14, 2005
Charly Travers
Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders. mark for My Articles similar articles
The Motley Fool
September 24, 2007
Brian Lawler
Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note. mark for My Articles similar articles
The Motley Fool
March 15, 2005
Charly Travers
PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 5, 2005
Charly Travers
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. mark for My Articles similar articles
The Motley Fool
August 8, 2007
Brian Lawler
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. mark for My Articles similar articles
The Motley Fool
May 3, 2005
Charly Travers
PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner. mark for My Articles similar articles
The Motley Fool
February 6, 2008
Brian Lawler
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. mark for My Articles similar articles
The Motley Fool
July 12, 2007
Brian Lawler
Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried. mark for My Articles similar articles
The Motley Fool
July 9, 2004
Charly Travers
Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL. mark for My Articles similar articles
The Motley Fool
September 28, 2007
Brian Lawler
Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs. mark for My Articles similar articles
The Motley Fool
November 12, 2007
Brian Lawler
What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note. mark for My Articles similar articles
The Motley Fool
March 16, 2007
Brian Lawler
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. mark for My Articles similar articles
The Motley Fool
May 30, 2008
Brian Lawler
PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs. mark for My Articles similar articles
The Motley Fool
January 26, 2005
Charly Travers
Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock. mark for My Articles similar articles
The Motley Fool
August 21, 2008
Brian Lawler
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. mark for My Articles similar articles
The Motley Fool
July 27, 2007
Brian Lawler
Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance. mark for My Articles similar articles
The Motley Fool
April 28, 2011
Brian Orelli
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. mark for My Articles similar articles
The Motley Fool
March 5, 2008
Brian Lawler
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring. mark for My Articles similar articles
The Motley Fool
May 7, 2008
Brian Lawler
PDL Delivers a Dividend The drugmaker's investors get a hefty payout. mark for My Articles similar articles
The Motley Fool
October 15, 2007
Brian Lawler
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 4, 2004
Charly Travers
Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not. mark for My Articles similar articles
The Motley Fool
November 6, 2006
Brian Lawler
Mixed Feelings About PDL The biopharmaceutical's third-quarter results look fine on the surface, but does deeper digging reveal some reasons for investors to be concerned? mark for My Articles similar articles
The Motley Fool
December 13, 2004
Charly Travers
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success. mark for My Articles similar articles
The Motley Fool
December 18, 2007
Brian Lawler
PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 27, 2006
Brian Lawler
Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 21, 2007
Brian Lawler
Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year. mark for My Articles similar articles
The Motley Fool
August 3, 2005
Charly Travers
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. mark for My Articles similar articles
The Motley Fool
August 22, 2006
Brian Lawler
Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company. mark for My Articles similar articles
The Motley Fool
January 12, 2005
Charly Travers
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. mark for My Articles similar articles
The Motley Fool
August 18, 2008
Brian Lawler
When Breaking Up Isn't Hard to Do PDL BioPharma and Enzon are the latest biotechs looking to spin off parts of their business. mark for My Articles similar articles
The Motley Fool
November 25, 2008
Brian Orelli
Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial. mark for My Articles similar articles
The Motley Fool
July 26, 2006
Brian Lawler
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. mark for My Articles similar articles
The Motley Fool
November 2, 2004
Charly Travers
Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth. mark for My Articles similar articles
The Motley Fool
September 26, 2007
Brian Lawler
Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma. mark for My Articles similar articles
The Motley Fool
February 25, 2008
Brian Lawler
A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer. mark for My Articles similar articles
The Motley Fool
January 29, 2008
Brian Lawler
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. mark for My Articles similar articles
The Motley Fool
June 29, 2007
Brian Lawler
Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 13, 2007
Brian Lawler
Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note. mark for My Articles similar articles
The Motley Fool
March 29, 2007
Brian Lawler
Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note. mark for My Articles similar articles
The Motley Fool
July 14, 2005
Charly Travers
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. mark for My Articles similar articles
The Motley Fool
July 10, 2008
Brian Lawler
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. mark for My Articles similar articles
The Motley Fool
May 21, 2004
Charly Travers
Protein Design Labs' Mixed Results Protein Design Labs' Nuvion looks like a winner, while other drugs stumble. Nuvion is in early clinical development for the treatment of severe ulcerative colitis and so far the results seem particularly compelling. mark for My Articles similar articles
The Motley Fool
August 29, 2006
Brian Lawler
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. mark for My Articles similar articles
The Motley Fool
July 15, 2008
Brian Lawler
Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings? mark for My Articles similar articles
The Motley Fool
April 14, 2008
Brian Lawler
Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results. mark for My Articles similar articles
The Motley Fool
March 17, 2008
Brian Lawler
Genentech Takes Center Stage There might be more partnerships in store for this drugmaker. mark for My Articles similar articles